BRYNJELSEN SEAN 4
4 · Eton Pharmaceuticals, Inc. · Filed Mar 3, 2023
Insider Transaction Report
Form 4
BRYNJELSEN SEAN
DirectorPresident & CEO10% Owner
Transactions
- Award
Stock Option (Right to buy)
2023-03-03+350,381→ 1,951,881 totalExercise: $3.47Exp: 2033-02-19→ Common Stock (350,381 underlying)
Footnotes (2)
- [F1]Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023.
- [F2]The Shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2027.